New stilbenes with vascular damaging activity
CA 2379544 A1 · Owner: Angiogene Pharmaceuticals Ltd. · Inventors: Davis, Peter David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A group of novel cis-stilbenes as disclosed of formula (1) wherein: R1 R2 and , R3 are each independently alkyl R4 is alkyl, haloalkyl, alkenyl, alkynyl alkylthio, alkylsulphinyl, alkylsulphonyl or halo R5 is hydrogen, alkoxy, alkyl, alkylthio hydroxy or halo, or a pharmaceutically acceptable salt thereof or a prodrug such as a phosphate ester. These compounds have vascular damaging activity and are therefore potentially of value in treatment of diseases where reversal of neovascularisation may have therapeutic benefit.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 9, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 9, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 9, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.